BUSINESS

Takeda CEO Weber to Retire Next Year, Succeeded by US Head

January 30, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Takeda Pharmaceutical said on January 30 that President and CEO Christophe Weber will retire from the company in June 2026 and be replaced by Julie Kim, currently president of the US Business Unit.The drug maker’s board of directors unanimously decided…

To read the full story

Julie Kim Tapped to Take Over Helm of Takeda in 2026
January 31, 2025

BUSINESS

Nxera Licenses GPCR Program to European VC-Backed Startup
February 13, 2026
Alfresa Launches Neffy Nasal Spray for Anaphylaxis in Japan
February 13, 2026
Datroway Filed for 1st-Line TNBC in Japan: Daiichi Sankyo
February 13, 2026
Teijin Seeks Japan Nod for Ascendis’s GHD Drug
February 13, 2026
Novo Targets Double-Digit Growth in Japan in 2026, Obesity Access Key
February 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Is Calling for an Abolition the Right Play? Rethinking Japan’s FY2027 Off-Year Drug Price Revision

By Ken Yoshino

Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…

COLUMN

AI in Healthcare Hiring: Leveling the Playing Field & Unlocking Human Potential

By Philip Carrigan

The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…